Phase 3 Readout~month

Phase 3 Topline: Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combin

Indication
Resectable MMR-deficient Solid Tumors; Resectable MMR-proficient Solid Tumors

Other upcoming events for AGEN

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patie
Phase 3 ReadoutPhase 3 Topline: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Col
Patent ExpiryPatent/Exclusivity Expiry: POSLUMA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combin — AGEN Phase 3 Readout | BioSniper